A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2014

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Continuous oral dosing at 150 mg daily.

DRUG

PF-00299804

Continuous oral dosing at 45mg daily

Trial Locations (59)

100

National Taiwan University Hospital, Taipei

112

Taipei Veterans General Hospital, Chest Department, Taipei

2050

Chris O'Brien Lifehouse, Camperdown

3065

St. Vincent's Hospital, Fitzroy

3220

The Andrew Love Cancer Centre,, Geelong

3690

Border Medical Oncology, Wodonga

15006

Hospital Teresa Herrera, A Coruña

20817

Center for Blood and Cancer Disorders, Bethesda

20850

Associates in Oncology/Hematology, PC, Rockville

26301

Oncology/Hematology Associates, Clarksburg

30033

Georgia Cancer Specialists, Decatur

30106

Northwest Georgia Oncology Center, Marietta

30303

Winship Cancer Institute at Grady Health Systems, Atlanta

30322

Winship Cancer Institute at Emory University, Atlanta

Winship Cancer Institute of Emory University, Atlanta

Winship Cancer Institute, Emory University, Atlanta

30501

The Longstreet Cancer Center, Gainesville

30901

Augusta Oncology Associates, P.C., Augusta

30909

Augusta Oncology Associates, PC, Augusta

31201

Central Georgia Cancer Care, P.C., Macon

31904

John B. Amos Cancer Center, Columbus

35661

Northwest Alabama Cancer Center, Muscle Shoals

38120

The West Clinic, Memphis

48903

Hospital de Cruces, Barakaldo

55455

University of Minnesota Cancer Center, Minneapolis

60099

Midwestern Regional Medical Center, Zion

83854

Kootenai Cancer Center at Post Falls, Post Falls

Kootenai Cancer Center, Post Falls

90640

Agajanian Institute of Oncology and Hematology, Montebello

169610

National Cancer Centre, Singapore

06610

Bridgeport Hospital, Bridgeport

06856

Wittingham Cancer Center @ Norwalk Hospital, Norwalk

06708

Medical Oncology & Hematology, P.C., Waterbury

30322-1013

Winship Cancer Institute, Emory University, Atlanta

31088-2259

Central Georgia Cancer Care, P.C., Warner Robins

90050-170

Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre

90610-000

Hospital Sao Lucas da PUCRS, Porto Alegre

14784-400

FUNDACAO PIO XII Hospital de Cancer de Barretos, Barretos

01246-000

Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, São Paulo

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

L4M 6M2

Royal Victoria Hospital, Barrie

L1G 2B9

RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa, Oshawa

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

Unknown

Department of Clinical Oncology, Shatin

Department of Clinical Oncology, Tuen Mun Hospital, Tuenmen

32-500

Medex spolka cywilna, Chrzanów

30-045

¿KardioDent¿, Krakow

31-108

"Vesalius Sp. z o.o.", Krakow

31-215

Zaklad Rentgena i USG Wyrobek spolka jawna, Krakow

00-728

Niepubliczny Zaklad Opieki Zdrowotnej AVI Centrum Medyczne, Warsaw

02-781

Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw

00716

Ponce School of Medicine / CAIMED Center, Ponce

110-744

Seoul National University Hospital, Seoul

120-752

Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul

135-710

SamsungMedicalCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine, Seoul

07198

Hospital Son Llatzer, Palma de Mallorca

08916

Hospital Universitari Germans Trias I Pujol, Badalona

M20 4BX

Christie Hospital NHS Foundation Trust, Manchester

OX3 7LJ

Churchill Hospital, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY